.png){kind=icon}
.png){kind=icon}
Return
Cyclin-dependent kinases as signaling integrators in cancer: Structural evolution, functional plasticity, and drug discovery
.png){kind=icon}
PRE
AI
S
S
M
M
DOI：10.1016/j.bbadis.2026.168364.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
• CDK catalytic cores exhibit conserved structural features with isoform-specific regulatory adaptations. • Gene duplication and sequence divergence have enabled functional repurposing of CDKs across eukaryotic evolution. • Non-canonical CDKs contribute to immune regulation, metabolic control, and synaptic plasticity. • PROTACs, covalent inhibitors, and AI-designed molecules represent next-generation CDK-targeting strategies. • CDK11, CDK14, and CDKL5 show emerging relevance in cancer, development, and neurodegeneration.
Keywords:
CDK
,
Cyclin-dependent kinase
CDKL
,
Cyclin-dependent kinase-like
CDKI
,
Cyclin-dependent kinase inhibitor
PROTAC
,
Proteolysis Targeting Chimera
ATP
,
Adenosine triphosphate
FDA
,
Food and Drug Administration
TME
,
Tumor microenvironment
CNS
,
Central nervous system
AI
,
Artificial intelligence
RNA polymerase II
,
RNA pol II
TFIIH
,
Transcription Factor IIH
IDR
,
Intrinsically disordered region
AML
,
Acute myeloid leukemia
BBB
,
Blood–brain barrier
HSP
,
Heat shock protein
CDK11
,
Cyclin-dependent kinase 11
CDK14
,
Cyclin-dependent kinase 14
CDKL5
,
Cyclin-dependent kinase-like 5
Cyclin-dependent kinases
Cell cycle regulation
Kinase inhibitors
Metabolic reprogramming
AI-driven drug discovery and autoimmune disorders
Journal
B
IF:
4.2
Papers:
497
Citations:
2.0W
Organization
View more organizations